FOXO Technologies outlines recent achievements and future plans, emphasizing growth and restructuring in healthcare sectors.
Quiver AI Summary
FOXO Technologies Inc. has provided a shareholder update from its newly appointed CEO, Seamus Lagan, reflecting on recent achievements and outlining future plans. Following a significant change in control and a successful second half of 2024, the company reports a shift from minimal revenues to potential annual profits exceeding $20 million with its acquired businesses. Improvements have been made to its balance sheet, including debt restructuring to meet NYSE American compliance. The focus for 2025 includes expanding its healthcare operations in rural hospitals and behavioral health services, along with possible new acquisitions in the healthcare sector. FOXO is also advancing its epigenetics division, aiming to innovate in personalized healthcare and considering a direct-to-consumer prognostic launch. The company operates three subsidiaries, including Myrtle Recovery Centers and Scott County Community Hospital, and is committed to significantly improving shareholder value while enhancing operations.
Potential Positives
- Change of control of the Company concluded, potentially leading to a successful turnaround and a foundation for profitable revenue growth.
- Acquisition of businesses that have the potential to deliver over $20 million in annual net revenues, indicating significant revenue growth prospects.
- Successful restructuring of over $21 million in shareholder equity, enhancing the Company's financial stability and compliance with NYSE American listing requirements.
- Plans to expand into additional healthcare sectors and potential acquisitions may further increase shareholder value.
Potential Negatives
- Significant shareholders' deficit in excess of $17 million reported as of September 30, 2024, indicating financial instability.
- Dependence on converting debt to equity through preferred stock, limiting immediate liquidity and potential market impact on common stock.
- Uncertainty surrounding the success of ongoing negotiations for additional acquisitions and restructuring efforts, implying potential risks in execution of the business strategy.
FAQ
What were the key achievements of FOXO Technologies in 2024?
In 2024, FOXO completed acquisition agreements, restructured debt, and created a foundation for generating over $20 million in net revenues.
What is FOXO Technologies' business strategy for 2025?
FOXO plans to expand acquired healthcare businesses and monetize its epigenetics division while exploring additional acquisition opportunities.
How is FOXO Technologies addressing shareholder equity?
The company restructured debt to equity, improving shareholder equity by over $21 million to meet NYSE American listing rules.
What services does Myrtle Recovery Centers provide?
Myrtle Recovery Centers offers detoxification, residential treatment, and outpatient services for opioid addiction and behavioral health.
What is the focus of FOXO Labs' technology?
FOXO Labs focuses on epigenetic biomarker discovery for enhancing human health and lifespan, integrating AI in personalized health solutions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FOXO Hedge Fund Activity
We have seen 8 institutional investors add shares of $FOXO stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 103,945 shares (+inf%) to their portfolio in Q3 2024, for an estimated $19,749
- VIRTU FINANCIAL LLC removed 52,243 shares (-57.3%) from their portfolio in Q3 2024, for an estimated $9,926
- UBS GROUP AG removed 39,402 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $7,486
- HRT FINANCIAL LP removed 38,752 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $7,362
- CAPITAL INVESTMENT ADVISORY SERVICES, LLC added 25,001 shares (+inf%) to their portfolio in Q4 2024, for an estimated $7,282
- CITADEL ADVISORS LLC added 23,923 shares (+inf%) to their portfolio in Q3 2024, for an estimated $4,545
- XTX TOPCO LTD added 12,298 shares (+90.1%) to their portfolio in Q3 2024, for an estimated $2,336
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MINNEAPOLIS, MN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), provides a brief shareholder letter from Seamus Lagan, recently appointed CEO of FOXO on what has been achieved in recent months and what is planned for 2025 and beyond.
Dear Fellow Shareholders,
Our recent shareholders meeting on January 17 th concluded the requirements of 2024 acquisition agreements and resulted in a change of control of the Company. The accomplishments in the second half of 2024 have been key to what we believe is becoming a very successful turnaround of our Company and has created a foundation from which we believe we can build a significant and profitable revenue-driven enterprise.
We have gone from having minimal net revenues since inception to having acquired businesses that that with investment, have the potential to deliver in excess of $20 million of profitable net revenues per annum.
We disclosed a shareholders deficit in excess of $17 million at September 30, 2024 and subsequently restructured a significant amount of debt to equity in the fourth quarter to meet NYSE American continued listing rules that require in excess of $4 million in shareholders’ equity, an improvement of in excess of $21 million in shareholders’ equity. We continue to negotiate with debt holders and have recently disclosed additional transactions of approximately $6 million of further debt being converted to equity. The majority of these transactions have been completed by issuing convertible preferred stock that cannot currently be converted to free trading of our Class A common stock.
Our business strategy for 2025 is to grow our acquired rural hospital and behavioral health businesses and pursue a strategy to monetize our existing epigenetics division. We are also actively seeking and evaluating additional acquisition opportunities in the healthcare sector, including senior living, which we may or may not be able to complete.
Current points of interest:
- We look forward to the timely filing of our 2024 audited financials in our Form 10-K.
- We are considering our options for the capital required to execute on our business strategy.
- We will continue to negotiate the potential exchange of existing debt and other liabilities to equity to improve our balance sheet.
- We are in preliminary discussions that may lead to additional acquisitions that we believe will increase shareholder value, however we have not reached agreement to complete any additional acquisitions at this time and we may not succeed in doing so.
-
We are in the process of restructuring our web site and social media and online presence to better inform our shareholders and interested parties of our services and ongoing accomplishments and provide details of our management team, Board of Directors and governance policies. We expect these work steps will be completed in the next 30-60 days
We operate three businesses;
Epigenetics: FOXO Lab’s., remains a pioneer in epigenetic biomarker discovery and commercialization. Our mission is to extend and enhance human life through advanced prognostics, therapeutic solutions, and lifestyle improvements. We have generated epigenetic data for over 13,000 individuals through internal research and external collaborations. This extensive dataset, paired with broad phenotypic information means the Company is well positioned for continued innovation and business growth in the rapidly evolving field of AI-driven healthcare and life span solutions. By combining the fields of epigenetics and artificial intelligence, FOXO Labs’ pioneering approach sets a new standard for personalized healthcare. The Company is now positioned to launch a direct-to-consumer prognostic that will provide actionable information and guidance to improve well-being and life span.
We will continue to consider all options to create value for our shareholders from this business, which may include a spin out at a time in the future if it is viable to do so. For more information about our technology, visit www.foxotechnologies.com
Myrtle Recovery Centers, Inc., operates a 30-bed behavioural health facility in East Tennessee. It provides inpatient services for Detoxification and Residential Treatment and outpatient services for Medication-assisted treatment (MAT) and Office-Based Opioid Treatment (OBOT) programs. The facility was opened in August 2023 and has secured in-network contracts with various insurance company payors. We anticipate growing this business to having profitable annual net revenues of approximately $3-4M and plan to replicate the service delivery model in other locations. More recently, we have seen significant increases in census as marketing efforts have intensified and additional payor contracts have been executed. Further information can be found at www.myrtlerecoverycenters.com
In the third quarter of 2024 we completed the acquisition of Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), a critical access designated (CAH) hospital located in East Tennessee. The hospital provides emergency services, outpatient services (including laboratory and radiology services) and inpatient services. We are considering options available to us to open additional hospital facilities at other locations in East Tennessee. Further information can be found at www.bsfmedical.com
The accomplishments of FOXO in recent months have resulted in a significant turnaround and created a number of attractive opportunities for the Company and its shareholders. We have challenges to overcome and objectives to achieve for 2025 and remain thankful for the continued support from our shareholders. My management team and I will endeavor to deliver results and accomplishments we can all be proud of and enjoy.
Sincerely
Seamus Lagan, CEO
About FOXO Technologies Inc. (“FOXO”)
FOXO owns and operates three subsidiaries.
Foxo Lab’s, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries.
Myrtle Recovery Centers, Inc., a 30-bed behavioural health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services for MAT and OBOT Programs.
Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical), a critical access designated (CAH) hospital in East Tennessee.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the FOXO’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
Sebastien Sainsbury
[email protected]
(561) 485-0151